MK-8558

MK-8558 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-8558, covering 2021-05-28 to 2021-05-28. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) [Phase 1]

See pricing